CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading organization profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

University of Hong Kong - Medical Cannabis Research Engine

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Organizations/education

education organization

University of Hong Kong

HK

OPENALEX: I889458895↗ROR: 02zhqgq86↗

People

Connected researchers

Albert K. ChungORCID 0000-0003-0490-3410 Andy Wai Kan YeungORCID 0000-0003-3672-357X Benjamin BeckerORCID 0000-0002-9014-9671 Cathryn M. LewisORCID 0000-0002-8249-8476 Cheuk Yin TseORCID 0000-0001-9005-8887 Daniel T. MyranORCID 0000-0002-8038-300X Douglas ManuelORCID 0000-0003-0912-0845 Erin HobinORCID 0000-0001-6335-2984 Evangelos VassosORCID 0000-0001-6363-0438 Jennifer XiaoExact authorship link Pak C. ShamORCID 0000-0002-2533-7270 Pak ShamExact authorship link Perry B.M. LeungORCID 0000-0002-5292-5641 Pui Hong ChungExact authorship link Robert TalaricoExact authorship link Rong NaORCID 0000-0001-7470-5108 Rosalie Liccardo PaculaORCID 0000-0002-6145-9865 Tom P. FreemanORCID 0000-0002-5667-507X Wing Chung ChangORCID 0000-0002-3581-8895

Public evidence

15 connected articles

Methylomic signature of current cannabis use in two first-episode psychosis cohorts.2025 · Europe PMC The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.2024 · Europe PMC A proof-of-concept analysis of data from the first NHS clinic for young adults with comorbid cannabis use and psychotic disorders.2024 · Europe PMC Determining the diagnostic cut-off on the Chinese version of severity of dependence scale for cannabis.2024 · Europe PMC Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study.2023 · Europe PMC First-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data2023 · PubMed Central Open Access The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.2023 · Europe PMC Cannabis Use Is Associated With Lower COVID-19 Susceptibility but Poorer Survival.2022 · PubMed Central Open Access A cross-sectional survey: Exploring future healthcare workers' intention to use cannabis through extended theory of planned behavior.2022 · PubMed Central Open Access Association between cannabis use with urological cancers: A population‐based cohort study and a mendelian randomization study in the UK biobank

Registered research

Connected studies

Testing the Efficacy of the Cannabis Clinic for Patients With Psychosis (CCP) Intervention for Cannabis Use Reduction/Cessation in Patients With First Episode Psychosisnct07245212

Matched by exact identifiers only. Profile data: OpenAlex.

2022 · PubMed Central Open Access

Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.2021 · PubMed Central Open Access

The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.2021 · PubMed Central Open Access

The Maudsley environmental risk score for psychosis.2020 · PubMed Central Open Access

Molecular neuroscience at its "high": bibliometric analysis of the most cited papers on endocannabinoid system, cannabis and cannabinoids.2019 · Europe PMC

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.2019 · PubMed Central Open Access